Our Lab team

oncgnostics GmbH has a R&D and a production department. Our lab team ist working on further improving the CE IVD marked GynTect assay, furthermore they are developing other assay systems (POCT, automation) and working on our pipeline projects on other cancer entities.

The whole company is working under a quality management system that is certified according to EN ISO 13485.

Dana Schmidt

Dana Schmidt

Pharma-Biotechnologist, assay development, QM-representative

Dana has joined oncgnostics in October 2012. She is responsible for test development and manages the quality management system according to ISO 13485 of oncgnostics. With her experience in the field of IVD she brought essential know-how into oncgnostics.

Kristina Wunsch

Kristina Wunsch

Research & development, lab technician

Kristina works for oncgnostics since October 2012. After an education as lab technician she has worked for several academic institutions and conpanies. With her long-term industry experience in reseach and development in the field of in-vitro diagnostics she is essential for our team. Besides experimental work in the R&D field, she organizes the oncgnostics lab.

Anne Hengst

Anne Hengst

Biotechnologist, Assay development

Anne has joined oncgnostics in September 2013, and she strengthens the GynTect® development team. She has acquired basic laboratory skills during studies for a BSc and MSc in biotechnology and together with Dana Schmidt she works in the test development.

Dr. Juliane Hippe

Dr. Juliane Hippe

Biologist, research

Juliane has studied biology at the Friedrich-Schiller University Jena. Already with her diploma thesis in the “Gynaecologic molecular biology” of the university women’s hospital she has contributed substantially to the GynTect® marker identification and validation. With her PhD thesis in collaboration between the Dürst lab and oncgnostics, she focused on the role of the GynTect® DNA methylation marker regions in carcinogenesis. Now she is responsible for the pipeline projects but also involved in the assay development.

Kristin Eichelkraut

Kristin Eichelkraut

Pharma-Biotechnologist, research & development

Kristin has joined oncgnostics in June 2015, and she works in the field of research and development. She performs assays for clinical trials and is responsible for the improvement of pre-analytics for a broader range of GynTect applications. Kristin has already performed the practical part of her MSc thesis (Pharma-Biotechnology) at oncgnostics.

Dr. Anne Hennig

Dr. Anne Hennig

Nutritionists, research & development

Anne has joined oncgnostics in April 2018, and she works in the field of research and development. Especially in our research projects ASSURER and MEDIKIT she is working on improving GynTect and developing new test systems like point-of-care and automation. Anne is experienced in cell biology and therefore strengthens our team specially in these projects.

Anna-Bawany Hums

Anna-Bawany Hums

Biologist, research

Bawany has joined oncgnostics in May 2017, and she works in the field of research and development. She has performed her master thesis about methylation markers in ovarian cancer and is now responsible for the pipeline product in the field of head and neck cancer detection.

Carolin Dippmann

Carolin Dippmann

Pharma-Biotechnologist, research

Carolin performs her PhD thesis in the field of basic research to explore the biology of the GynTect marker regions.

Theresa Erler

Theresa Erler

Pharma-biotechnologist, master student

Theresa performs her master thesis in the field of our pipeline project, the detection of head and neck cancer.